Lopinavir/Ritonavir Dosage Form Affects Quality of Life During Monotherapy in HIV-Positive Adults

Abstract

This was a single-center, open-label study of lopinavir/ritonavir (LPV/r) single-agent therapy in antiretroviral-naive, HIV-infected participants initiating therapy with twice-daily soft-gelatin capsules (SGC) and switched to tablets after ≥4 weeks. The objective was to evaluate quality of life and tolerability of the 2 formulations. Participants quality of life, depression, and tolerability were measured using the Medical Outcomes Study-HIV (MOS-HIV), Modified Global Condition Improvement (GCI), and Center for Epidemiologic Studies-Depression (CES-D), prior to and 4 weeks following switch. MOS-HIV showed significant improvements in general health perception (+6 (16), mean (SD); P = .047) and role functioning (+8 (19), mean (SD); P = .023) post-switch. GCI showed significant improvement in ease of taking medications with tablets (56.7% vs 83.3%; P = .021). No change was observed in CES-D. Tolerability improved in 47%. Reported diarrhea (grade 2) was higher during SGC (33.3% vs3.3%; P = .004). Quality-of-life measures, tolerability, and diarrhea improved with the LPV/r tablet formulation compared to SGC in HIV-positive patients not receiving other antiretroviral therapy (ART).

Keywords

lopinavir protease inhibitors tolerability tablets quality-of-life

References

Eron J., Jr , Yeni P. , Gathe J. Jr , et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368(9534):476-482.

Murphy RL , da Silva BA , Hicks CB , et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials . 2008;9(1):1-10.

Bertz R. , Lam W. , Brun S. , et al. Multiple-dose pharmacokinetics of ABT-378/ritonavir in HIV+ subjects [Abstract 327]. Paper presented at 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, CA.

Kaletra [package insert]. Abbott Park, IL: Abbott Laboratories; 2009 April.

Bertz R. , Renz C. , Foit C. , et al. Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100 mg BID) in HIV-infected subjects when taken with food [Poster 3, 10] . Paper presented at 2nd International Workshop on Clinical Pharmacology of HIV Therapy; April 2-4, 2001; Noordwijk, Netherlands.

Klein CE , Chiu YL , Awni W. , et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007; 44(4):401-410.

Bonfanti P. , Valsecchi L. , Parazzini F. , et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr . 2000;23(3): 236-245.

d’Arminio Monforte A. , Lepri AC , Rezza G. , et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14(5):499-507.

Lucas GM , Chaisson RE , Moore RD Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131(2):81-87.

10.

Spiller RC , Brown ML , Phillips SF Decreased fluid tolerance, accelerated transit, and abnormal motility of the human colon induced by oleic acid. Gastroenterology. 1986;91(1):100-107.

11.

Schrader S. , Chuck SK , Rahn LW , Parekh P. , Emrich KG Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules. AIDS Res Ther. 2008;5:21.

12.

Bierman WF , van Agtmael MA , Nijhuis M. , Danner SA , Boucher CA HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review . AIDS. 2009;23(3):279-291.

13.

Gathe Jr JC , Yeh RF , Mayberry C. , et al. Single-agent Therapy with Lopinavir/ritonavir Suppresses Plasma HIV-1 Viral Replication in HIV-1 naive subjects: IMANI-2 48 Week Results [Abstract 1518]. Paper presented at 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007 ; Sydney, Australia.

14.

Wu AW , Jacobson DL , Berzon RA , et al. The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS. Qual Life Res. 1997;6(1):3-10.

15.

Wu AW , Revicki DA , Jacobson D. , Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res . 1997;6(6):481-493.

16.

Kohout FJ , Berkman LF , Evans DA , Cornoni-Huntley J. Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index. J Aging Health. 1993; 5(2):179-193.

17.

The Adult AIDS Clinical Trials Group Table for Grading Severity of Adult Adverse Experiences.

18.

Johnson M. , Grinsztejn B. , Rodriguez C. , et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006; 20(5):711-718.

19.

Riddler SA , Haubrich R. , DiRienzo AG , et al. Class-sparing regimens for initial treatment of HIV-1 infection . N Engl J Med. 2008; 358(20):2095-2106.

20.

Singer J. , Thorne A. , Phillips P. , et al. Predictors of survival and eradication of Mycobacterium avium complex bacteremia (MAC) in AIDS patients in the Canadian randomized MAC treatment trial. Canadian HIV Trials Network Protocol 010 Study Group. AIDS. 1999;13(5):575-582.

21.

Feinberg JE , Hurwitz S. , Cooper D. , et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group J Infect Dis. 1998;177(1):48-56.

22.

Revicki DA , Moyle G. , Stellbrink HJ , Barker C. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter PISCES (SV14604) Study Group.AIDS. 1999; 13(7):851-858.

23.

Safrin S. , Finkelstein DM , Feinberg J. , et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsonetrimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996 ;124(9):792-802.

24.

Ofotokun I. , Chuck SK , Schmotzer B. , O’Neil KL Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients. AIDS Res Ther. 2009;6:29.

25.

Torpey K. , Kasonde D. , Goma F. The experience of patients taking the lopinavir/ritonavir (LPV/r) tablet compared with the LPV/r soft-gel capsule in Zambia. Int J STD AIDS . 2008;19(suppl 1):1-4.

26.

Lubeck DP , Bennett CL , Mazonson PD , Fifer SK , Fries JF Quality of life and health service use among HIV-infected patients with chronic diarrhea. J Acquir Immune Defic Syndr. 1993 ;6(5): 478-484.

27.

Tramarin A. , Parise N. , Campostrini S. , et al. Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy . Qual Life Res. 2004;13(1): 243-250.

28.

Siddiqui U. , Bini EJ , Chandarana K. , et al. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol. 2007;41(5):484-490.